Open Search
Search
中EN

Products

We are dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs

  • Product Center

    QLETLI® - the first Adalimumab biosimilar in China

  • Pipeline

    Innovation for life

    • Process and Manufacture

    We have established a comprehensive quality management system in compliance with requirements applicable to and enforced by global competent authorities

    Explore Further

    Company News

    Bio-Thera Solutions Expands Partnership with Dr. Reddy’s through an Exclusive Commercialization and License Agreement for BAT2306, a Proposed Biosimilar Candidate to Cosentyx® (Secukinumab), in Southe

    Guangzhou, China; November 10, 2025: Bio-TheraSolutions (688177:SH; “Bio-Thera”), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative therapies and biosimilars, today annou...

    Bio-Thera Solutions Announces the Launch of STARJEMZA® (ustekinumab-hmny) in the United States

    GUANGZHOU,China - Bio-Thera Solutions (688177.SH), a commercial-stage biopharmaceutical companydeveloping innovative therapies and biosimilars, announced that its partner, HikmaPharmaceuticals USA Inc...

    Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License A

    GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative therapies and biosimilars, todayannounced an expansion of its part...

    © 2019 Bio-Thera Solutions, Ltd. All Rights Reserved. 粤ICP备17106513号